NEW YORK, Jan. 29, 2016 /PRNewswire/ -- Dipexium Pharmaceuticals, Inc. (NASDAQ: DPRX), a late stage pharmaceutical company focused on the development and commercialization of Locilex® (pexiganan cream 0.8%), a novel, broad spectrum, topical antibiotic peptide, today announced that David P. Luci, President & Chief Executive Officer, will present a corporate overview at the 18th Annual BIO CEO & Investor Conference in New York City, on Tuesday, February 9, 2015 at 9:30 a.m. Eastern Time.
To access the live audio webcast of the presentation, please log on through a link located in the Investor Relations section of Dipexium's website at www.dipexiumpharmaceuticals.com, under the IR Calendar tab. A replay of the webcast will be available one hour after the conclusion of the live event.
About Dipexium Pharmaceuticals, Inc.
Dipexium Pharmaceuticals, Inc. (NASDAQ: DPRX) is a late-stage pharmaceutical company focused on the development and commercialization of Locilex® (pexiganan cream 0.8%), a novel, broad spectrum, topical antibiotic peptide. Initially, Locilex® is targeted for the treatment of mild infections of diabetic foot ulcers. Based on a compilation of available clinical and microbiology data, Locilex® is also considered a promising product candidate to treat other mild and moderate skin and skin structure infections, including infected decubitus ulcers, infected burns, infected surgical wounds and nasal colonization of methicillin-resistant staphylococcus aureus (MRSA).
David P. Luci President & Chief Executive Officer Dipexium Pharmaceuticals, Inc. 212-269-2834 firstname.lastname@example.org
David Garrett Vice President, Finance & Corporate Development Dipexium Pharmaceuticals, Inc. 212-269-2834 email@example.com
© 2016 Dipexium Pharmaceuticals, Inc. All rights reserved.
SOURCE Dipexium Pharmaceuticals, Inc.